SCHEMBL2430508

SCHEMBL2430508

COC(=O)[C@@H]1C[C@@H](OCc2cccc(-c3cccc(Br)c3)c2)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 4/20 0.41
KLK5 Q9Y337 1/20 0.40
CTSL P07711 1/20 0.38
AAK1 Q2M2I8 3/20 0.37
REN P00797 2/20 0.37
CTSB P07858 1/20 0.37
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
USP30 Q70CQ3 1/20 0.35
ABCB1 P08183 1/20 0.35
CYP3A4 P08684 2/20 0.35
THRB P10828 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
XIAP P98170 1/20 0.34
BIRC3 Q13489 1/20 0.34
BIRC2 Q13490 1/20 0.34
ACE P12821 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4307660 0.93 CACNA1B (0.40) CACNA1BCTSLAAK1RENCTSB
SCHEMBL2426240 0.89 KLK5 (0.40) CACNA1BKLK5CTSLRENCTSB
SCHEMBL8227117 0.83 USP30 (0.43) USP30ABCB1
SCHEMBL4294862 0.83 ACE (0.40) CACNA1BKLK5CTSLRENCTSB
SCHEMBL2430509 0.80 CACNA1B (0.39) CACNA1BKLK5CTSLAAK1REN
SCHEMBL8228152 0.74 CYP3A4 (0.38) CYP3A4THRBHSD17B10
SCHEMBL2431251 0.74 ABCB1 (0.34) ABCB1XIAPBIRC3BIRC2
SCHEMBL2427392 0.74 F2 (0.35) ABCB1CYP3A4THRBHSD17B10
Hydrochloric Acid SCHEMBL2429662 0.74 CYP3A4 (0.38) CYP3A4THRBHSD17B10
SCHEMBL8241586 0.74 ELANE (0.40) CACNA1BKLK5CTSLAAK1CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314062-B2 Macrocyclic compounds as antiviral agents INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2012-11-20 US disclosed
US-8314062-B2 Macrocyclic compounds as antiviral agents INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2012-11-20 US disclosed
EP-2041159-B1 MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS ANGELETTI P IST RICHERCHE BIO (IT) 2011-09-28 EP disclosed
US-20090312241-A1 Macrocyclic Compounds as Antiviral Agents ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-12-17 US disclosed
US-20090312241-A1 Macrocyclic Compounds as Antiviral Agents ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312241-A1 Macrocyclic Compounds as Antiviral Agents ZC3HAV1, ZC3HAV1L, HAVCR2 CACNA1B 3771/4885KLK5 4392/4885CTSL 549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.